As clinical-grade inhibitors of Pol θ are currently in development (58), our study suggests that combined inhibition of both DNA-PK and Pol θ represents a promising strategy to reverse therapeutic DNA damage resistance in p53-deficient cancers. The gene discussed is TP53; the disease is cancer.